NanoVibronix Announces Positive Results from Independent Product Trial of UroShield for Patients with a Spinal Cord Injury
March 14 2023 - 9:15AM
Business Wire
Evaluators concluded that UroShield has the
potential to improve quality of life and reduce healthcare
associated costs
NanoVibronix, Inc., (NASDAQ: NAOV) (the “Company”), a
medical device company utilizing the Company's proprietary and
patented low intensity surface acoustic wave (SAW) technology,
today announced the positive evaluation results for its UroShield
device, presented at a recent medical conference by clinicians from
the Royal National Orthopaedic Hospital (“RNOH”).
The report concluded that the Company’s UroShield device showed
a decrease in the number of blockages and infections and an
increase in catheter satisfaction in the patients studied. In
addition, evaluators concluded that the device has the potential to
improve quality of life and reduce healthcare associated costs for
patients with spinal cord injuries who experience recurrent
blockages or infections and who have complicated catheter
issues.
“This report is further affirmation of the benefits and efficacy
of our UroShield,” stated Brian Murphy, Chief Executive Officer of
NanoVibronix. “Feedback collected from patients that participated
in the study affirms that UroShield is straightforward to use, of
benefit to patients’ physical and mental health and in at least one
case, was instrumental in preventing a hospital stay. UroShield is
available to all NHS clinicians and their patients who need the
device with full clinical support, through the NHS supply chain. We
are encouraged by the increasing support for UroShield and positive
outcomes that patients are experiencing.”
Murphy added, “It is estimated that approximately 285,000 people
in the United States1 and approximately 50,000 people in the United
Kingdom2 are living with a spinal cord injury and new incidents are
being added each year. Accordingly, we believe patients suffering
with a spinal cord injury represents a clear and specific use case
and measurable market opportunity for UroShield.”
The product evaluation was conducted by clinicians - Claire
Riley, Sarah Knight, Frank Lee, Hannah Houliston and Rizwan Hamid
of the London Spinal Cord Injury Centre, Royal National Orthopaedic
Hospital, Stanmore, UK. The evaluation is being submitted for
publication and the full text will be available after publication.
For a poster presentation regarding the product evaluation, please
visit
https://az659834.vo.msecnd.net/eventsairwesteuprod/production-zibrant-public/29641f634e024972800471993e9c3b96.
About NanoVibronix, Inc.
NanoVibronix, Inc. (NASDAQ: NAOV) is a medical device company
headquartered in Elmsford, New York, with research and development
in Nesher, Israel, focused on developing medical devices utilizing
its patented low intensity surface acoustic wave (SAW) technology.
The proprietary technology allows for the creation of low-frequency
ultrasound waves that can be utilized for a variety of medical
applications, including for disruption of biofilms and bacterial
colonization, as well as for pain relief. The devices can be
administered at home without the assistance of medical
professionals. The Company’s primary products include PainShield®,
UroShield® and WoundShield®, all of which are portable devices
suitable for administration at home without assistance of medical
professionals. Additional information about NanoVibronix is
available at: www.nanovibronix.com.
Forward-looking Statements
This press release contains “forward-looking statements.” Such
statements may be preceded by the words “intends,” “may,” “will,”
“plans,” “expects,” “anticipates,” “projects,” “predicts,”
“estimates,” “aims,” “believes,” “hopes,” “potential” or similar
words. Forward-looking statements are not guarantees of future
performance, are based on certain assumptions and are subject to
various known and unknown risks and uncertainties, many of which
are beyond the Company’s control, and cannot be predicted or
quantified; consequently, actual results may differ materially from
those expressed or implied by such forward-looking statements. Such
risks and uncertainties include, without limitation, risks and
uncertainties associated with: (i) market acceptance of our
existing and new products or lengthy product delays in key markets;
(ii) negative or unreliable clinical trial results; (iii) inability
to secure regulatory approvals for the sale of our products; (iv)
intense competition in the medical device industry from much
larger, multinational companies; (v) product liability claims; (vi)
product malfunctions; (vii) our limited manufacturing capabilities
and reliance on subcontractor assistance; (viii) insufficient or
inadequate reimbursements by governmental and/or other third party
payers for our products; (ix) our ability to successfully obtain
and maintain intellectual property protection covering our
products; (x) legislative or regulatory reform impacting the
healthcare system in the U.S. or in foreign jurisdictions; (xi) our
reliance on single suppliers for certain product components; (xii)
the need to raise additional capital to meet our future business
requirements and obligations, given the fact that such capital may
not be available, or may be costly, dilutive or difficult to
obtain; (xiii) our conducting business in foreign jurisdictions
exposing us to additional challenges, such as, e.g., foreign
currency exchange rate fluctuations, logistical and communications
challenges, the burden and cost of compliance with foreign laws,
and political and/or economic instabilities in specific
jurisdictions; and (xiv) market and other conditions. More detailed
information about the Company and the risk factors that may affect
the realization of forward-looking statements is set forth in the
Company’s filings with the Securities and Exchange Commission
(SEC), including the Company’s Annual Report on Form 10-K and its
Quarterly Reports on Form 10-Q. Investors and security holders are
urged to read these documents free of charge on the SEC’s web site
at: http://www.sec.gov. The Company assumes no obligation to
publicly update or revise its forward-looking statements as a
result of new information, future events, or otherwise, except as
required by law.
_______________ 1
https://msktc.org/sites/default/files/lib/docs/Data_Sheets_/SCIMS_Facts_and_Figures_2017_August_FINAL.pdf
2 https://www.aspire.org.uk/our-purpose
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230314005748/en/
Investor Contacts: Brett Maas, Managing Principal, Hayden
IR, LLC brett@haydenir.com (646) 536-7331
NanoVibronix (NASDAQ:NAOV)
Historical Stock Chart
From Jul 2024 to Aug 2024
NanoVibronix (NASDAQ:NAOV)
Historical Stock Chart
From Aug 2023 to Aug 2024